ABSTRACT
The purpose of this study was to define a method for assessing skeletal tumor burden with 18 F-sodium fluoride PET/CT (fluoride-PET/CT) and evaluate the reproducibility of these measurements.
METHODS: Ninety-eight consecutive patients (90 males; 65.7 ± 14.2yrs.)
underwent 158 fluoride-PET/CT scans for evaluation of skeletal metastatic disease. Normal bone mean SUVs were measured over a 1 cm spherical volume of interest (VOI) placed over 5 bone sites: T12, L5, sacrum, right iliac and right femur. For each patient, average SUVs for all sites was generated. Afterwards, a threshold value of normal bone uptake was established. Subsequently, skeletal tumor burden was determined by generating volumetric data using a whole-body segmentation method. All
SUVs below the established normal threshold value were excluded from analysis as were VOIs not related to metastatic disease. Statistics for the remaining VOIs were then generated and defined as the skeletal tumor burden by two parameters: total fluoride skeletal metastatic lesion uptake (TLF10) and the total volume of fluoride avid bone metastases (FTV10).
TLF10 and FTV10 reproducibility was determined using two independent and experienced PET/CT readers performing analysis on a subset of 13 fluoride-PET/CTs.
INTRODUCTION
Radionuclide bone scanning is a frequently-used imaging study to determine the presence and extent of skeletal metastases in a variety of malignancies, such as prostate carcinoma and breast carcinoma. Beyond disease detection and tumor staging, there is a critical role for imaging in the prediction and determination of therapy response. The aim of this study is to propose a method for semi-quantitative assessment of total skeletal tumor burden using fluoride-PET/CT , to evaluate the reproducibility of these measurements, and through examples illustrate how these volumetric measures may be applied. Whole-body non-contrast CT scans were used for attenuation correction.
MATERIALS AND METHODS
Images were reconstructed iteratively and displayed in 2.5 mm slices in the transverse, coronal and sagittal planes.
Determination of Normal Bone Values on Fluoride-PET/CT
Fluoride-PET/CT studies were displayed and evaluated using a MIM Vista workstation (MIM Vista, Cleveland, OH). evaluable, the measurement of that specific abnormal site was excluded for that particular patient. An average SUV for all evaluable sites was then generated for each patient.
Determination of Skeletal Tumor Burden on Fluoride-PET/CT
Skeletal tumor burden was determined by generating volumetric data using a whole-body segmentation method.
A semi-automatic VOI was drawn in the whole-body image of each patient with caution to encompass all metastatic sites. After the wholebody VOI was drawn, the lower threshold boundary for determination of a VOI was set at an SUV of 10 (according to the established threshold value of normal bone uptake). In addition to excluding any uptake below the established norm al threshold (SUV = 10), careful image review was then undertaken in order to determine if a lesion was benign or malignant.
All images were interpreted evaluating the 18 F-fluoride uptake as well as the anatomical images on the CT portion of the scan, in order to manually exclude sites of elevated 18 F-fluoride uptake which were not related to metastatic disease, such as the urinary activity in the renal collecting system, degenerative disease, healing fractures, etc. (Fig 1) .
Afterwards, volumetric parameters of skeletal fluoride uptake were obtained from the statistics generated with the final volumetric extraction.
Using an SUV=10 threshold, skeletal tumor burden was determined by calculating the volume of total fluoride activity within the VOI (FTV10), and the total fluoride lesion uptake as a product of SUVmean x VOI10 (TLF10).
After 
Statistical Analysis
Pearson's product-moment correlation coefficient was used to measure the extent of linear dependence between bone SUVmean and age. 
RESULTS

Normal Bone Values on Fluoride-PET/CT
A total of 158 fluoride-PET/CTs performed on 98 patients were evaluated. Among the 158 18 F-Sodium fluoride-PET/CTs, 86 scans were acquired for staging and 72 for subsequent treatment strategy (58 scans were acquired after the 4 th radium-223 dose and 14 were acquired three months after the last dose). Sixteen studies were not evaluable due to extensive metastatic disease and no measureable sites of normal bone (equivalent to a "superscan"). Therefore, normal bone SUV measurements were obtained from the remaining 142 fluoride-PET/CTs, with a total of 543 sites assessed. The results of the normal bone SUV measurements are displayed in Table 1 . No patient had more than 2 non-evaluable sites.
The average normal SUV for all 543 sites was 5.32 ± 0.99. There was no relationship between the patient's bone SUVmean value at the 5 measured by However, not all tumors can be adequately evaluated with FDG PET/CT. For many tumor types, bone scintigraphy plays an essential role, through its ability to detect bone metastases, especially osteoblastic disease.
However, the assessment of disease extent and response on conventional bone scintigraphy has been challenging.
There is preliminary evidence that more extensive the disease detected by scintigraphy, the worse the outcome (22, 23) . Initially, a 5-point grading system was developed to visually quantify skeletal tumor burden on bone scintigraphy (22) , however, counting number of lesions is not practical. An objective means of quantifying skeletal tumor burden on bone scintigraphy was subsequently elaborated, although the quantification was manually performed and therefore not practical to be implemented on a routine basis (24) . Finally, a semi-automatic method was elaborated to quantify skeletal tumor burden on bone scintigraphy which showed correlation to survival (25) . Tc-MDP, the former has a higher uptake and blood clearance, which leads to fluoride-PET/CT having faster acquisition time and images performed earlier (15 to 30 minutes after radiotracer injection) (27, 28) . PET/CT images have a better spatial resolution when compared to conventional scintigraphy and even when compared to SPECT/CT. For example, fluoride-PET/CT is ideal for staging and restaging prostate cancer patients, due to greater sensitivity, specificity and accuracy when compared to conventional bone scintigraphy (29) . Additionally, fluoride-PET/CT has been of great value in defining equivocal bone metastases in prostate cancer patients when compared to bone scintigraphy (29) , (30, 31) .
To our knowledge this is the first study to describe the assessment of skeletal tumor burden using the intrinsic semiquantitative and Other thresholds could be employed using this technique. In general, the lower the threshold for volumetric extraction, the more potential disease sites will be included in the final parameters. However, this comes at a cost of including increasing amounts of normal bone in the final measurements. Raising the threshold (to say, SUV = 15 or 20), will diminish the potential for normal bone inclusion and may increasingly exclude sites of benign activity such as degenerative change, but will also progressively exclude sites of metastatic disease with low uptake. At this time, it is not clear which thresholds will provide the optimal information for clinical decision-making, and further studies will be needed. Although we provisionally suggest a threshold of 10 (generating TLF10 and FTV10) as a means to determine overall disease burden, higher thresholds (e.g. TLF50)
may also impart valuable information by differentiating areas of high bone turnover from areas of more quiescent disease.
Determining skeletal tumor burden with fluoride-PET/CT (TLF10 and/or FTV10) may also help guide patient management. 
